Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ICCB280 was capable of inducing differentiation and apoptosis of ATRA-resistant patient blasts strongly signify that the activity of this compound can overcome resistance to other current therapies for AML with an unfavorable prognosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 74.00 | |
2 mg | In stock | $ 108.00 | |
5 mg | In stock | $ 178.00 | |
10 mg | In stock | $ 322.00 | |
25 mg | In stock | $ 522.00 | |
50 mg | In stock | $ 759.00 | |
100 mg | In stock | $ 1,060.00 | |
500 mg | In stock | $ 2,130.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 197.00 |
Description | ICCB280 was capable of inducing differentiation and apoptosis of ATRA-resistant patient blasts strongly signify that the activity of this compound can overcome resistance to other current therapies for AML with an unfavorable prognosis. |
Targets&IC50 | Others:8.6 μM |
In vitro | ICCB280 (10 μM; 2-8 d) increases the C/EBPα expression (mRNA and protein) and modulates its target genes in HL-60 cells.ICCB280 (0.1-50 μM; 48 h) suppresses the HL-60 cell growth, with an IC50 of 8.6 μM[1]. |
Molecular Weight | 386.4 |
Formula | C23H18N2O4 |
CAS No. | 2041072-41-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 85mg/mL (219.98mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ICCB280 2041072-41-5 Apoptosis Others Inhibitor ICCB-280 ICCB 280 differentiation proliferation C/EBPα anti-leukemic inhibit inhibitor